Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study

Background/aimsTo evaluate the efficacy and safety of individualised 2.0 mg intravitreal aflibercept retreatment for diabetic macular oedema (DME) through the fifth year of management.MethodsThis is a phase IV, 2-year, open-label extension study. Sixty patients completing the 3-year VISTA DME (Study...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of ophthalmology 2018-05, Vol.102 (5), p.631-636
Hauptverfasser:	Wykoff, Charles C, Ou, William C, Khurana, Rahul N, Brown, David M, Lloyd Clark, W, Boyer, David S
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical trials Consent Diabetes Diabetic retinopathy Edema FDA approval Lasers Ophthalmology Patients Retina Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!